Compare Incyte Corporation (INCY) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ThredUp Inc — how do they compare? Incyte Corporation trades at $120.55 (market cap $24.48B), while ThredUp Inc trades at $3.2 (market cap $405.82M). The key difference: Incyte Corporation is far larger — about 60.3× ThredUp Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| INCY | TDUP | |
|---|---|---|
Market Cap | $24.48B | $405.82M |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $12.08 |
52-Week Low | $81.66 | $3.08 |
Enterprise Value | $19.98B | $404.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.52, down 0.45% on the day but maintains strong momentum with a 23% gain year-to-date in 2026. The stock shows bullish technical signals with moving averages supporting upward trends, while recent Q2 2026 earnings beat expectations with EPS of $3.09 versus $2.15 estimate. Revenue growth continues with 2025 reaching $5.14B and projected 2026 revenue of $5.8B, supported by strong product sales including Jakafi and Opzelura.
Outlook remains positive with analyst consensus price target of $122.82 representing 1.9% upside potential. Key opportunities include continued revenue growth and recent EU approval for Opzelura, while risks involve competitive pressures and the stock's proximity to 52-week highs. The company's strong profitability metrics with 27.71% net margin and 30.67% ROE support fundamental strength.
ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.
The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
